We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
Read MoreHide Full Article
Sanofi (SNY - Free Report) announced that the European Commission has approved a rare blood disorder drug, Cablivi (caplacizumab) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
This is the first drug to receive approval for this indication. This may help the drug to gain leading market share with first-mover advantage in this indication.
The decision was expected as the Committee for Medicinal Products for Human Use (“CHMP”) had recommended the drug’s approval in July.
The FDA has also accepted the Biologics License Application for caplacizumab under priority review for a similar indication. A decision is expected on Feb 6, 2019.
Sanofi had added caplacizumab to its pipeline with the acquisition of Belgium-based Ablynx earlier this year for €3.9 billion after bidding out Novo Nordisk (NVO - Free Report) .
The company’s stock has lost 0.4% so far this year against the industry’s decrease of 4.6%.
The approval was based on data from phase II TITAN study and phase III HERCULES study. The drug in combination with current standard-of-care significantly shortened time to platelet count response. It also significantly reduced in aTTP-related death, recurrence of aTTP, or at least one major thromboembolic event.
The blood disorder is a fatal disease, which causes death among 20% of patients treated with current standard-of-care within 30 days of diagnosis.
Sanofi is focused on strengthening its leadership in rare diseases, especially developing treatment for rare blood disorders that have significant unmet need. The company also acquired Bioverativ this year, which added a hemophilia candidate to its pipeline. It also acquired global rights for fitusiran from Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) , which is being developed for the treatment of hemophilia A and B.
Lilly’s earnings per share estimates have increased from $5.15 to $5.47 for 2018 and from $5.47 to $5.69 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 10.15%. The stock has increased 25.1% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Sanofi's Blood Disorder Drug Cablivi Gets Approval in Europe
Sanofi (SNY - Free Report) announced that the European Commission has approved a rare blood disorder drug, Cablivi (caplacizumab) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
This is the first drug to receive approval for this indication. This may help the drug to gain leading market share with first-mover advantage in this indication.
The decision was expected as the Committee for Medicinal Products for Human Use (“CHMP”) had recommended the drug’s approval in July.
The FDA has also accepted the Biologics License Application for caplacizumab under priority review for a similar indication. A decision is expected on Feb 6, 2019.
Sanofi had added caplacizumab to its pipeline with the acquisition of Belgium-based Ablynx earlier this year for €3.9 billion after bidding out Novo Nordisk (NVO - Free Report) .
The company’s stock has lost 0.4% so far this year against the industry’s decrease of 4.6%.
The approval was based on data from phase II TITAN study and phase III HERCULES study. The drug in combination with current standard-of-care significantly shortened time to platelet count response. It also significantly reduced in aTTP-related death, recurrence of aTTP, or at least one major thromboembolic event.
The blood disorder is a fatal disease, which causes death among 20% of patients treated with current standard-of-care within 30 days of diagnosis.
Sanofi is focused on strengthening its leadership in rare diseases, especially developing treatment for rare blood disorders that have significant unmet need. The company also acquired Bioverativ this year, which added a hemophilia candidate to its pipeline. It also acquired global rights for fitusiran from Alnylam Pharmaceuticals, Inc. (ALNY - Free Report) , which is being developed for the treatment of hemophilia A and B.
Sanofi Price
Sanofi Price | Sanofi Quote
Zacks Rank & Stock to Consider
Sanofi currently has a Zacks Rank #4 (Sell).
Eli Lilly and Company (LLY - Free Report) is a better-ranked stock from the same space, carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Lilly’s earnings per share estimates have increased from $5.15 to $5.47 for 2018 and from $5.47 to $5.69 for 2019 over the past 60 days. The company delivered a positive earnings surprise in all the trailing four quarters with an average beat of 10.15%. The stock has increased 25.1% so far this year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>